Merck and Moderna prepare to file personalized mRNA cancer vaccine for approval
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Following a successful Phase 3 trial in August that showed Merck and Moderna's personalized mRNA cancer vaccine significantly delayed melanoma recurrence and metastatic disease, the companies are preparing to file for approval. While patient Gary Keblish remains cancer-free and teaching after participating in the trial, the companies are now planning to explore the vaccine's efficacy across a broader range of tumors.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu